SGLT2 Inhibitor Reduces Risk for Dementia, Alzheimer's in T2D
Patients with type 2 diabetes treated with SGLT2is showed significant reductions in the risk for Alzheimer's disease, vascular dementia, and other neurodegenerative conditions.
Medscape Medical News
source https://www.medscape.com/viewarticle/sglt2-inhibitor-reduces-risk-neurodegenerative-diseases-t2d-2024a1000gmm?src=rss
Medscape Medical News
source https://www.medscape.com/viewarticle/sglt2-inhibitor-reduces-risk-neurodegenerative-diseases-t2d-2024a1000gmm?src=rss
Comments
Post a Comment